Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease
- 1 February 1997
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 349 (9051) , 521-524
- https://doi.org/10.1016/s0140-6736(97)80083-9
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- European trial of cyclosporine in chronic active Crohn's disease: A 12-month studyGastroenterology, 1995
- Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology, 1995
- THE THERAPEUTIC EFFECTS OF AN ENGINEERED HUMAN ANTI-TUMOUR NECROSIS FACTOR ALPHA ANTIBODY (CDP571) IN RHEUMATOID ARTHRITISRheumatology, 1995
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- Enhand secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's diseaseClinical and Experimental Immunology, 1993
- Tumour-necrosis-factor antibody treatment in Crohn's diseaseThe Lancet, 1993
- CD4 Antibody Treatment in Crohn's DiseaseScandinavian Journal of Gastroenterology, 1992
- A Placebo-Controlled, Double-Blind, Randomized Trial of Cyclosporine Therapy in Active Chronic Crohn's DiseaseNew England Journal of Medicine, 1989
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980